Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.

NCT00751205 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00751205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00751205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
August 31, 2010
Enrollment
150 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, prostate cancer